JP2009529541A - 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤 - Google Patents

代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤 Download PDF

Info

Publication number
JP2009529541A
JP2009529541A JP2008558554A JP2008558554A JP2009529541A JP 2009529541 A JP2009529541 A JP 2009529541A JP 2008558554 A JP2008558554 A JP 2008558554A JP 2008558554 A JP2008558554 A JP 2008558554A JP 2009529541 A JP2009529541 A JP 2009529541A
Authority
JP
Japan
Prior art keywords
purin
amine
ethyl
pyridin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529541A5 (OSRAM
Inventor
アンドリュー ジー． コール
マークーラーレー ブレスシア
ジョアン ジェー． チャン
ザーヒド フサイン
デービッド ジェー． ディラー
アクセル メッツガー
ガルツァー アハメド
イアン ヘンダーソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacopeia LLC
Original Assignee
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Inc filed Critical Pharmacopeia Inc
Publication of JP2009529541A publication Critical patent/JP2009529541A/ja
Publication of JP2009529541A5 publication Critical patent/JP2009529541A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008558554A 2006-03-09 2007-03-09 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤 Pending JP2009529541A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78080006P 2006-03-09 2006-03-09
PCT/US2007/063699 WO2007104053A2 (en) 2006-03-09 2007-03-09 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009529541A true JP2009529541A (ja) 2009-08-20
JP2009529541A5 JP2009529541A5 (OSRAM) 2010-04-30

Family

ID=38371082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558554A Pending JP2009529541A (ja) 2006-03-09 2007-03-09 代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤

Country Status (12)

Country Link
US (2) US7951803B2 (OSRAM)
EP (1) EP1991547A2 (OSRAM)
JP (1) JP2009529541A (OSRAM)
KR (1) KR20080107466A (OSRAM)
CN (1) CN101454325A (OSRAM)
AU (1) AU2007222982A1 (OSRAM)
BR (1) BRPI0709007A2 (OSRAM)
CA (1) CA2646429A1 (OSRAM)
EA (1) EA014907B1 (OSRAM)
MX (1) MX2008011525A (OSRAM)
WO (1) WO2007104053A2 (OSRAM)
ZA (1) ZA200807715B (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525377A (ja) * 2010-04-23 2013-06-20 サイトキネティクス・インコーポレーテッド ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法
JP2016530259A (ja) * 2013-08-14 2016-09-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジノン

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
CA2666940A1 (en) * 2006-10-20 2008-05-02 N.V. Organon Purines as pkc-theta inhibitors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102186856B (zh) 2008-08-22 2014-09-24 诺华股份有限公司 作为cdk抑制剂的吡咯并嘧啶化合物
US20130065883A1 (en) 2010-02-18 2013-03-14 Centro Nacional de Investigaceiones Oncologicas (CNIO) Triazolo [4, 5- B] Pyridin Derivatives
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
ES2635262T3 (es) 2012-11-09 2017-10-03 Evotec International Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
JP6457523B2 (ja) 2013-12-04 2019-01-23 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシイミン置換キナゾリン
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
AU2015257917C1 (en) 2014-05-07 2019-03-14 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
CN105001096B (zh) * 2015-07-21 2017-07-21 沈阳化工研究院有限公司 一种制备4‑氨基‑n‑烷基苄胺的方法
CN106008506B (zh) * 2016-06-27 2018-02-13 山东大学 取代嘌呤类衍生物及其制备方法与应用
CN120284862A (zh) 2018-12-07 2025-07-11 纽罗克里生物科学有限公司 用于治疗先天性肾上腺皮质增生症的crf1受体拮抗剂、其药物制剂和固体形式
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006465A1 (en) * 2001-07-13 2003-01-23 Cv Therapeutics, Inc. Partial and full agonist of a adenosine receptors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
AU711592B2 (en) 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
EP1439863B1 (en) 2001-10-29 2011-01-12 Boehringer Ingelheim International GmbH Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
US7105526B2 (en) * 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20090054358A1 (en) * 2004-07-19 2009-02-26 The John Hopkins University Flt3 inhibitors for immune suppression
KR20070085286A (ko) * 2004-10-29 2007-08-27 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 바이사이클릭 피리미딘 유도체
KR20080013886A (ko) * 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
WO2008043031A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
CA2666940A1 (en) * 2006-10-20 2008-05-02 N.V. Organon Purines as pkc-theta inhibitors
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US20080220256A1 (en) * 2007-03-09 2008-09-11 Ues, Inc. Methods of coating carbon/carbon composite structures

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006465A1 (en) * 2001-07-13 2003-01-23 Cv Therapeutics, Inc. Partial and full agonist of a adenosine receptors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525377A (ja) * 2010-04-23 2013-06-20 サイトキネティクス・インコーポレーテッド ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法
JP2016530259A (ja) * 2013-08-14 2016-09-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジノン

Also Published As

Publication number Publication date
CA2646429A1 (en) 2007-09-13
EP1991547A2 (en) 2008-11-19
WO2007104053A3 (en) 2007-11-01
KR20080107466A (ko) 2008-12-10
EA014907B1 (ru) 2011-02-28
MX2008011525A (es) 2008-09-18
ZA200807715B (en) 2009-11-25
US7951803B2 (en) 2011-05-31
US20110230480A1 (en) 2011-09-22
WO2007104053A2 (en) 2007-09-13
US20080032971A1 (en) 2008-02-07
EA200801897A1 (ru) 2009-02-27
CN101454325A (zh) 2009-06-10
BRPI0709007A2 (pt) 2011-06-21
AU2007222982A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
US7951803B2 (en) 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders
JP4324338B2 (ja) 縮合イミダゾール化合物及び糖尿病治療薬
TWI676620B (zh) 離胺酸特異性去甲基酶-１之抑制劑
US20230219946A1 (en) Pyrimidin-4(3h)-one heterocyclic compound, preparation method thereof, and pharmaceutical use thereof
TWI729109B (zh) 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
AU2014249050A1 (en) Histone dementhylase inhibitors
WO2014143799A9 (en) Substituted xanthines and methods of use thereof
JPWO2001002400A1 (ja) 縮合イミダゾール化合物及び糖尿病治療薬
JP2012500805A (ja) 免疫抑制のための６−置換２−（ベンズイミダゾリル）プリンおよびプリノン誘導体ならびに６−置換２−（イミダゾロ［４，５−ｃ］ピリジニル）プリンおよびプリノン誘導体
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
JP2021512161A (ja) Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ−インダゾール誘導体およびその治療上の使用
KR20190104142A (ko) 신규 옥소이소퀴놀린 유도체
WO2021011796A1 (en) Inhibitors of cyclin-dependent kinases
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
WO2021099838A1 (en) Adenosine receptor antagonist compounds
KR20230163335A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
TW202342444A (zh) 特定化學實體、組合物及方法
US20240150337A1 (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR101869144B1 (ko) 포스포디에스테라아제 10 억제제(pde-10)로서 신규 피리미딘 유도체
WO2022240826A1 (en) Heterocyclic derivatives as camkk2 inhibitors
SK142099A3 (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
TW202246261A (zh) 作為抗癌劑的化合物
TW202540091A (zh) 新型分子作為ｄｎａ損傷修復途徑的抑制劑
WO2021147790A1 (zh) 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
HK40077081A (en) Adenosine receptor antagonist compounds

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130521